NOTICE OF INTENTION TO RENAME A PHARMACEUTICAL PRODUCT CURRENTLY APPROVED UNDER THE GMS & COMMUNITY DRUG SCHEMES



This form has been prepared to enable manufacturers, importers or their agents to notify the HSE Corporate Pharmaceutical Unit of a Name Change of an approved Pharmaceutical Product.

1.	Name, strength, form and pack size of a pharmaceutical product currently:	
2.	GMS/High Tech code:	
3.	Proposed new name:	
5.	Marketing authorisation number:	
7.	Proposed date for name change:	
8.	Proposals for informing the National Medicines Information Centre:	
9.	Give reasons for the proposed name change of the product(s) with appropriate substantiating information:	
10.	Provide details of the current status and availability of the product in the various Member States of the European Union:	
11.	A copy of any letter(s) sent or proposed to be sent to Health Care Professionals in relation to the name change of the product:	
12.	A copy of the Summary of Products Characteristics of the old and proposed new name of the product:	
13.	Fee for Name change to an existing reimbursed product:	
14.	Company Name:	
15.	Company Address:	
16.	Contact Name:	
17.	Telephone No:	
18.	Email Address:	

Signed: Managing Director/General Manager	Date:
The completed form should be returned to: Corporate Pharmaceutical Unit HSE Primary Care Reimbursement Service Exit 5 M50 North Road Dublin 11 D11 XKF3	
Tel No: 353-1-8915725 Fax No: 353-1-8915757 E-mail: <u>CPU@hse.ie</u>	

Copies of this form are available on www.hse.ie/eng/about/Who/cpup

CPU Office Use Only - Date Stamp	ffice Use Only - Date Stamp	

The following documents must be enclosed with this form:				
1) Company Cover Letter				
2) Patient Information Leaflet				
3) Product Artwork				
4) Licence (EU and/or HPRA)				
5) Summary of Products Characteristics				
6) Letter to Healthcare Professionals				
7) Name change fee				